Editas Medicine Business Update
Editas Medicine received approval to initiate its Phase 1/2 Strive clinical trial for EDIT-401 in Australia, targeting patients with heterozygous familial hypercholesterolemia. The company expects to begin patient dosing in 2026 and report initial safety and tolerability data in the first quarter of 2027. Additionally, the company will present new preclinical data demonstrating durable LDL-C reduction at the AHA Scientific Sessions in November 2026.
- Counterparty
- Therapeutic Goods Administration